including a recent approval in neoadjuvant/adjuvant treatment of early-stage non-small cell lung cancer (NSCLC). It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a ...
Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous ... but picked up its first approval in the rare tumour Merkel cell carcinoma last year. Incyte had previously ...
Aspirin and COX-1 inhibitors boost immunity against cancer metastasis, revealing a new pathway for anti-metastatic therapies.
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
San Francisco, US Tuesday, April 1, 2025, 15:00 Hrs [IST] ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback